Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 3/20 | 0.52 |
| ▸ | EGFR | P00533 | 6/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.51 |
| ▸ | KDR | P35968 | 11/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12303702 | 1.00 | RET (0.52) | RETEGFRERBB2KDRFLT3 | |
| SCHEMBL28480333 | 0.87 | RET (0.41) | RETEGFRERBB2KDRFLT3 | |
| SCHEMBL9975298 | 0.77 | EGFR (0.57) | RETEGFRERBB2KDR | |
| SCHEMBL20155722 | 0.75 | EGFR (0.39) | RETEGFRERBB2KDRFLT3 | |
| SCHEMBL2451218 | 0.74 | RET (0.57) | RETEGFRERBB2KDRFLT3 | |
| SCHEMBL1105383 | 0.74 | EGFR (0.75) | RETEGFRERBB2KDRFLT3 | |
| SCHEMBL4733212 | 0.74 | EGFR (0.71) | EGFRERBB2KDR | |
| SCHEMBL1105407 | 0.74 | EGFR (0.71) | EGFRERBB2KDR | |
| SCHEMBL12303657 | 0.74 | RET (0.57) | RETEGFRERBB2KDRFLT3 | |
| SCHEMBL1096859 | 0.74 | EGFR (0.75) | RETEGFRERBB2KDRFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106045918-A | Substituted pyrimidine derivatives with Akt inhibiting activity, and preparation method and application thereof | 山东大学 | 2016-10-26 | — | — | CN | disclosed |
| US-8013153-B2 | Substituted pyrimidine kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-09-06 | — | — | US | disclosed |
| US-20070254896-A1 | SUBSTITUTED PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254896-A1 | SUBSTITUTED PYRIMIDINE KINASE INHIBITORS | DTYMK, TK1, DCK | RET 577/4885EGFR 1449/4885ERBB2 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.